BBIO - BridgeBio Pharma - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BBIO is currently covered by 11 analysts with an average price target of $66.58. This is a potential upside of $20.28 (43.8%) from yesterday's end of day stock price of $46.3.

BridgeBio Pharma's activity chart (see below) currently has 117 price targets and 126 ratings on display. The stock rating distribution of BBIO is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 65.5% with an average time for these price targets to be met of 263.07 days.

Highest price target for BBIO is $95, Lowest price target is $46, average price target is $59.36.

Most recent stock forecast was given by DAVID LEBOWITZ from CITI on 11-Jul-2025. First documented stock forecast 22-Jul-2019.

Currently out of the existing stock ratings of BBIO, 54 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$67

$20.7 (44.71%)

$49

15 days ago
(11-Jul-2025)

3/5 (60%)

$20.53 (44.18%)

294

Buy

$54

$7.7 (16.63%)

$45

1 months 1 days ago
(25-Jun-2025)

5/7 (71.43%)

$9.62 (21.68%)

191

Buy

$56

$9.7 (20.95%)

$53

1 months 17 days ago
(09-Jun-2025)

18/25 (72%)

$16.97 (43.48%)

333

Buy

$72

$25.7 (55.51%)

$54

2 months 26 days ago
(30-Apr-2025)

3/6 (50%)

$33.64 (87.70%)

360

Buy

$55

$8.7 (18.79%)

$52

2 months 26 days ago
(30-Apr-2025)

5/8 (62.5%)

$16.64 (43.38%)

227

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BBIO (BridgeBio Pharma) average time for price targets to be met?

On average it took 263.07 days on average for the stock forecasts to be realized with a an average price target met ratio 65.5

Which analyst has the current highest performing score on BBIO (BridgeBio Pharma) with a proven track record?

TYLER VAN BUREN

Which analyst has the most public recommendations on BBIO (BridgeBio Pharma)?

Tyler Van Buren works at TD COWEN and has 5 price targets and 3 ratings on BBIO

Which analyst is the currently most bullish on BBIO (BridgeBio Pharma)?

Josh Schimmer with highest potential upside - $48.7

Which analyst is the currently most reserved on BBIO (BridgeBio Pharma)?

Eun Yang with lowest potential downside - -$22.3

BridgeBio Pharma in the News

BridgeBio Pharma's SWOT analysis: stock poised for growth on strong pipeline

BridgeBio Pharma, Inc. (NASDAQ:BBIO), with its current market capitalization of $8.3 billion, has garnered significant attention from analysts in recent months, with many viewing the company as undervalued given its strong product launch and robust late-stage pipeline. The stock has demonstrated remarkable momentum, delivering a 70% return over the past year and trading near its...

High Growth Tech Stocks In The US Market May 2025

Over the last 7 days, the United States market has risen by 2.7%, contributing to a 9.6% increase over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market trends....
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?